CYTOF — Altamira Therapeutics Balance Sheet
0.000.00%
- $0.33m
- -$0.31m
Annual balance sheet for Altamira Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | R2021 December 31st | 2022 December 31st | R2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 20-F | 20-F | 20-F | 20-F | 20-F |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | fx Final | fx Final | fx Final | Final | Final |
Cash | |||||
Cash and Short Term Investments | 12.7 | 1.08 | 0.017 | 0.734 | 0.999 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 0.091 | 0.76 | 0.825 | 0.089 | 0.351 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 13.1 | 4.49 | 1.91 | 1.45 | 1.54 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 0.053 | 0.619 | 0.482 | 0.095 | 0.45 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Total Assets | 23.5 | 21 | 6.82 | 9.14 | 8.65 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 3.42 | 5.33 | 13.9 | 1.06 | 1.16 |
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 4.55 | 6.72 | 15.8 | 1.47 | 2.09 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 18.9 | 14.3 | -8.99 | 7.68 | 6.57 |
Total Liabilities & Shareholders' Equity | 23.5 | 21 | 6.82 | 9.14 | 8.65 |
Total Common Shares Outstanding |